Endothelins (ETs) are a family of three peptides (ET-, ET-, ET-) that are implicated in the physiological control of vascular smooth muscle cell (VSMC) and myocardial contractility and growth. ET- is vasoactive peptide that acts via ET-A receptors coupling inducing vascular smooth muscle cell contraction. ET- is involved in the development and maintenance of hypertension. Aim of this study was to investigate whether ET- can induce vascular smooth muscle cell proliferation through arachidonic acid (AA) metabolites formed via cytochrome P¬ (CYP-). ese results suggest AA metabolites via CYP- mediates ET- induce VSMC proliferation.
Introduction
Vasoactive agents such as norepinephrine (NE), angiotensin II (ANG II), and endothelin- can induce hypertrophy and proliferation of vascular smooth muscle cell and thus be implicated in pathogenesis of hypertension (-) . Endothelins (ETs) are a family of three peptides (ET-, ET-, ET-) that are implicated in the physiological control of vascular smooth muscle cell (VSMC) and myocardial contractility and growth. ET- is vasoactive peptide that acts via ET-A receptors coupling inducing vascular smooth muscle cell contraction (-) . ET- induces arachidonic acid release via activation of cytosolic phospholipase A (cPLA) () . Arachidonic acid is metabolized by cyclooxygenase into prostaglandins, by lipoxygenase into leukotrienes and by cytochrome P- into -, -, and -HETE (, ) . It has been reported that NE and ANG II induce arachidonic acid release via activation of CaMK II and cPLA (, ) . The metabolites of arachidonic acid generated via cytochrome P- and lypoxygenase contribute to development of hypertension and vascular smooth muscle cell proliferation (, , ) . Aim of this study was to investigate whether ET- can induce vascular smooth muscle cell proliferation through arachidonic acid (AA) metabolites formed via cytochrome P¬. 
Materials and Methods

Materials
Statistical Analysis
Values are expressed as mean ± SEM. The data were analyzed by -way ANOVA, and difference between the means for multiple comparisons was determined by the Newman-Keuls test and a value difference of p<, was considered statistically signifi cant.
Results
To determine the effect of ET- on vascular smooth muscle cell proliferation aortic vascular smooth muscle cells made quiescent for  hours (M- arresting medium), were exposed to ET-.
ET- increased [
 H]thymidine incorporation in VSMC in a concentration dependent manner ( Figure ) .
COX, LO and Citochrome P- monooxygenase metabolite arachidonic acid into prostaglandins, leukotrienes and -, -HETE, respectively. To determine whether activities of these enzymes and their metabolites are involved in ET- induced VSMC pro- 
Discussion
It has been previously reported that norepinephrine (NE) and angiotensin II (ANG II) increase CaM kinase II and cPLA activities and thus release arachidonic acid () . e metabolites of arachidonic acid, such as -and -HETE made via cytocrome P- and lipoxygenase, through Ras/MEK/MAPK pathway activation contribute to vascular smooth muscle cell proliferation induced by NE or ANG II (, ) . ET- is vasoactive peptide that acts via ET-A receptors coupling inducing vascular smooth muscle cell contraction. ET- is involved in vascular smooth muscle cell growth and in the development and maintenance of hypertension. ET- promotes vascular smooth muscle cell proliferation through extracellular signal-regulated kinase activation () . ET- induced arachidonic acid release is mediated by cPLA activation in rat tail artery () . Our study indicates that CYP- and LO metabolites of AA, -hydroxyeicosatetraenoic acid (HETE) and -HETE increased ET--induced VSMC proliferation. at the metabolites of arachidonic acid generated via CYP- and LO but not COX, induce VSMC proliferation was indicated by fi nding that exogenous arachidonic acid, like ET-, increased [  H]thymidine incorpora¬tion into VSMC and this was inhibited by -ODYA and baicalein, but not by indomethacin. ET- induced VSMC proliferation was independent prostaglandins. e effect of NE and ANG II to stimulate VSMC proliferation has also been reported to be not altered by the COX inhibitors () . NE, ANG II and arachidonic acid metabolites have been shown to increase MAPK activity (, , , ) in VSMC. Our fi nding that inhibitors of MAP kinase (PD-) and cPLA (MAFP) attenuated ET- as well as -HETE induced VSMC proliferation suggest that ET- induced VSMC proliferation is mediated by CYP- and LO products of arachidonic acid through cPLA  and MAP kinase activation.
Conclusion
e present study demonstrates that ET- promotes vascular smooth muscle cell proliferation through activation of cPLA resulting in arachidonic acid release. Arachidonic metabolites -, -HETE generated by LO and CYP- induce vascular smooth muscle cell proliferation by activating MAP kinase. 
